Vestagistin instructions:


Vestagistin manufacturer:

"Pharmascience Inc.", Canada

Active substance Vestagistine:

1 tablet contains betagistine hydrochloride - 16.0mg

Forms of release of Vestagistin:

Tablets 8 mg No. 30

Tablets of 16 mg No. 30

To whom is shown Vestagistin:

Disease and Ménière syndrome. Symptomatic treatment of vestibular vertigo.

How to use Vestagistin:

Dose is selected individually depending on the effect.

Tablets 8 mg: 1-2 tablets 3 times a day.

Tablets of 16 mg: ½-1 tablet 3 times daily

The daily intake for adults is 24-48 mg, evenly distributed throughout the day. The drug should be taken after meals.

Symptom reduction is sometimes observed only after 2-3 weeks of treatment. The best results are achieved with taking the drug for several months. There is evidence that the use of the drug at the onset of the disease prevents its progress

ion and hearing loss in the later stages.

Use during pregnancy or lactation.

There is no reliable data that the use of the drug during pregnancy affects the mother and fetus. However, during pregnancy, the drug should be taken only if there is undoubted need and under the direct supervision of a doctor.

Patient with gastric ulcer and duodenal ulcer in the history of the drug should be administered with caution. During treatment, it is necessary to monitor the condition of patients with bronchial asthma and pheochromocytoma.

The ability to influence the reaction rate when driving or other machinery.

No studies of the effect of the drug on the reaction rate in the management of motor vehicles or other mechanisms have been carried out.

It is not recommended to use the drug during lactation. The isolation of betahistine in breast milk has not been studied. Benefit from the use of the drug should be correlated with the benefits of breastfeeding and the potential risk to the child.


Children are not recommended. The efficacy and safety of betahistine for children under 18 years of age have not been studied.

Side effects of vestagistin:

The following adverse reactions were observed at a frequency( very frequent ≥ 1/10, frequent from ≥ 1/100 to <1/10, infrequent from ≥ 1/1 000 to <1/100, single from ≥1/10 000 to <1/1 000, rare & lt; 1 / 10,000).

From the gastrointestinal tract.

Frequent: nausea, indigestion.

Infrequent: vomiting, pain in the abdominal region, a feeling of heaviness in the epigastrium, flatulence.

These side effects disappear when taking the drug with food or after reducing the dose.

Immune system disorders.

Hypersensitivity reactions, including negative type( there have been reports of rare cases of anaphylaxis development).

From the skin and subcutaneous tissue.

Rare: hypersensitivity to the skin and subcutaneous fat, in particular angioedema, rash, itching and urticaria.

To whom is contraindicated? Vestagistin:

Hypersensitivity to the drug components. Pheochromocytoma.

Interaction of vestagistin:

The in vitro study data suggest the absence of inhibition of the activity of cytochrome P450 in vivo .The interaction of the drug Vestagistin with other drugs in vivo is unknown.

Overdose of vestagistin:

There are reports of single cases of drug overdose. In most cases, the clinical symptoms of an overdose were absent. Sometimes after taking doses of the drug more than 200 mg, mild and moderate symptoms were observed, such as stomach pain, nausea, drowsiness. There are reports of seizures in overdose( 640 mg) with the appearance of symptoms of mild to moderate severity. All cases ended in complete recovery.

Treatment of overdose should include symptomatic therapy.